Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future.
- Published in:
- CNS Drugs, 2024, v. 38, n. 1, p. 15, doi. 10.1007/s40263-023-01059-8
- By:
- Publication type:
- Article
Works matching IS 11727047 AND DT 2024 AND VI 38 AND IP 1
Results: 6
1
2
Effect of Levetiracetam on Cognition: A Systematic Review and Meta-analysis of Double-Blind Randomized Placebo-Controlled Trials.
- Published in:
- CNS Drugs, 2024, v. 38, n. 1, p. 1, doi. 10.1007/s40263-023-01058-9
- By:
- Publication type:
- Article
3
Insulin Resistance/Diabetes and Schizophrenia: Potential Shared Genetic Factors and Implications for Better Management of Patients with Schizophrenia.
- Published in:
- CNS Drugs, 2024, v. 38, n. 1, p. 33, doi. 10.1007/s40263-023-01057-w
- By:
- Publication type:
- Article
4
Treatment of Sleep, Motor and Sensory Symptoms with the Orexin Antagonist Suvorexant in Adults with Idiopathic Restless Legs Syndrome: A Randomized Double-Blind Crossover Proof-of-Concept Study.
- Published in:
- CNS Drugs, 2024, v. 38, n. 1, p. 45, doi. 10.1007/s40263-023-01055-y
- By:
- Publication type:
- Article
5
Thrombolysis with Recombinant Human Prourokinase 4.5–6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial.
- Published in:
- CNS Drugs, 2024, v. 38, n. 1, p. 67, doi. 10.1007/s40263-023-01051-2
- By:
- Publication type:
- Article
6
Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia
- Published in:
- CNS Drugs, 2024, v. 38, n. 1, p. 55, doi. 10.1007/s40263-023-01056-x
- By:
- Publication type:
- Article